Epidermal Growth Factor Receptor C797S
1 clinical trials · Condition
◉ Watch Epidermal Growth Factor Receptor C797S
| Record | Firm | Date |
|---|---|---|
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations (NCT05256290) | Black Diamond Therapeutics, Inc. | 2022-03-31 |
Track Epidermal Growth Factor Receptor C797S automatically
Every clearance here is in the API, with alerts when new ones post.